Remdesivir will only be available at the "government price" to smaller government programs, excluding Medicare and Medicaid. Dr. Peter Bach proposes two options if Gilead wishes to offer the discounts to the full array of government programs.
The COVID-19 urgency for vaccine development has popularized a false dichotomy that risk taking that involves forgoing traditional regulatory protocol leads to an expedited timeline for developing effective treatments.
Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today.
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019. The bill, if passed, would allow Medicare to negotiate drug prices using 120% of international reference price as the payment upper limit.
Together with Mark Trusheim of MIT Sloan School of Management and Preston Atteberry, MD, the Drug Pricing Lab team articulated why biosimilars are not and will not effectively lower the price of biologic drugs after the period of market exclusivity.
Preston J. Atteberry, Peter B. Bach, Jennifer A. Ohn, Mark R. Trusheim
Dr. Stacie Dusetzina and Dr. Peter Bach present an analysis of the implications of the Trump Administration’s proposed changes to eliminate Medicare Part D rebates from drug manufacturers, published in JAMA.
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.